Figure 5. Granzyme C-expressing ILC1s expand and mediate cancer immunosurveillance in the PyMT model of breast cancer.

A. Abundance of CXCR6⁺CD49a⁺NK1.1⁺CD3⁻ (CXCR6⁺CD49a⁺), Eomes⁺CD49a⁺NK1.1⁺CD3⁻ (Eomes⁺CD49a⁺) and CD49a⁻CD49b⁺NK1.1⁺CD3⁻ (NK) cells out of total CD45⁺ cells in PyMT tumors. Expression of S1pr5^eGFP (B), granzyme C (GzmC) (C), S1pr5^FM (D), and Gzmc^FM (E) in CXCR6⁺CD49a⁺ ILC1 (red), Eomes⁺CD49a⁺ ILC1 (blue), and CD49a⁻CD49b⁺ NK cell (green) populations in PyMT tumors of S1pr5^eGFPPyMT (B), PyMT (C), S1pr5^FMPyMT chimera (D), and Gzmc^FMPyMT (E) mice. F. Abundance of ILC1s in tumors of PyMT (white bar) and GzmC^iCreTgfbr2^fl/flPyMT (Gzmc^ΔTgfbr2PyMT) (gray bar) mice, quantifying CD49a⁺ cells among NK1.1⁺CD3⁻ cells and CD103⁺ and GzmC⁺ cells among CD49a⁺NK1.1⁺CD3⁻ cells in the tumor. G. Tumor volume at 12 and 16 weeks of age from PyMT (white bar) and Gzmc^ΔTgfbr2PyMT (gray bar) mice. H. Abundance of ILC1s in tumors of PyMT (white bar) and GzmC^iCreRosa26^LSL-DTA/+ PyMT (Gzmc^DTAPyMT) (black bar) mice, quantifying CD49a⁺ cells among NK1.1⁺CD3⁻ cells and CD103⁺ and GzmC⁺ cells among CD49a⁺NK1.1⁺CD3⁻ cells in the tumor. I. Tumor volume at 12 and 16 weeks of age from PyMT (white bar) and Gzmc^DTAPyMT (black bar) mice. Each dot represents one mouse (n = 5–9 mice per group). All data are combined from three or more independent experiments and shown as mean +/− SEM (unpaired student’s t-test for two groups, one-way ANOVA with Tukey’s multiple comparisons test with more than two groups, “ns” = not significant, * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001).